Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1320P - Impact of body mass index (BMI) in non-small cell lung cancer patients treated with anti PD-1 immunotherapy (IO): A retrospective cohort study


17 Sep 2020


E-Poster Display



Tumour Site

Non-Small Cell Lung Cancer


Ana Catarina Bravo


Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283


A.C. Bravo1, S.L. Lobo-Martins2, I. Vendrell2, A.B. Mansinho2, C. Melo-Alvim2, D. Hasmucrai3, A.S. Vilariça3, P. Alves3, E. Teixeira3, R. Teixeira de Sousa2, C. Bárbara3, L. Costa2

Author affiliations

  • 1 Lisbon School Of Medicine, Lisbon University, 1649-028 - Lisboa/PT
  • 2 Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte (CHULN)- Hospital Santa Maria (HSM), 1649-035 - Lisboa/PT
  • 3 Oncological Pneumology, Centro Hospitalar Universitário Lisboa Norte (CHULN)- Hospital Pulido Valente (HPV), 1769-001 - Lisboa/PT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1320P


Being overweight or obese is an established risk factor for many malignancies and is associated with worse outcomes in several cancers. Although it is characterized by a metainflammatory state, little is understood about its impact in response to IO. Some studies in metastatic melanoma and renal cell carcinoma patients receiving IO demonstrated that being overweight or obese is associated with longer progression free survival (PFS) and overall survival (OS), and recently some studies have pointed towards a similar association in NSCLC. This study aimed to explore the impact of BMI in NSCLC patients treated with anti PD-1 IO.


This is a retrospective cohort study of NSCLC patients with advanced disease treated with pembrolizumab (≥1st line) or nivolumab (≥2nd line) in monotherapy. Patients were categorized into BMI<25 Kg/m2 and BMI≥25 Kg/m2 according to WHO definition.


114 patients were included, 70.2% male and 37.7% with BMI≥25 Kg/m2. Both groups were balanced in all characteristics except for less active smokers (p=0,034), more tumors with PD-L1 expression≥50% (p=0.025) and more dyslipidemic patients (p=0.047) in the BMI≥25 Kg/m2 group. Although in univariate analysis there was no association between BMI and PFS (HR=1.029; 95% CI 0.660-1.605; p=0.898) or OS (HR=1.012; 95% CI 0.638-1.607; p=0.959), in the multivariate model correcting for PD-L1 expression, hepatic and/or central nervous system metastasis, PS-ECOG and dyslipidemia, patients with BMI≥25 Kg/m2 had worse outcomes, both in PFS (HR=2.180; 95% CI 1.049-4.532; p=0.037) and OS (HR=2.364; 95% CI 1.062-5.263; p=0,035). Curiously, dyslipidemia was associated with better PFS in both univariate analysis (HR=0.572; 95% CI 0.355-0.920; p=0.021) and multivariate model (HR=0.421; 95% CI 0.206-0.859; p=0.017).


A BMI≥25 Kg/m2 was associated with shorter PFS and OS in our cohort. Our results differ from other studies, reinforcing the complex relationship between overweight, inflammation and IO response. The association found between dyslipidemia (not studied on previous studies) and PFS may suggest other factors play a role in this relationship and should be further investigated.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.